BME:EEP

Stock Analysis Report

Executive Summary

Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally.

Snowflake

Moderate growth potential with mediocre balance sheet.

Share Price & News

How has Euroespes's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EEP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.6%

EEP

-0.9%

ES Life Sciences

0.6%

ES Market


1 Year Return

5.1%

EEP

8.1%

ES Life Sciences

3.1%

ES Market

Return vs Industry: EEP underperformed the Spanish Life Sciences industry which returned 8.1% over the past year.

Return vs Market: EEP exceeded the Spanish Market which returned 3.1% over the past year.


Shareholder returns

EEPIndustryMarket
7 Day1.6%-0.9%0.6%
30 Day13.8%5.1%1.3%
90 Day3.3%1.8%6.5%
1 Year5.1%5.1%9.2%8.1%6.9%3.1%
3 Year-6.1%-6.1%82.9%73.5%21.1%9.6%
5 Year14.8%14.8%241.0%214.8%13.1%-6.7%

Price Volatility Vs. Market

How volatile is Euroespes's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Euroespes undervalued compared to its fair value and its price relative to the market?

0.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EEP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EEP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EEP is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: EEP is unprofitable, so we can't compare its PE Ratio to the Spanish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EEP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EEP is good value based on its PB Ratio (0.8x) compared to the XE Life Sciences industry average (3.9x).


Next Steps

Future Growth

How is Euroespes forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EEP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: EEP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EEP's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if EEP's revenue is forecast to grow faster than the Spanish market.

High Growth Revenue: Insufficient data to determine if EEP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EEP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Euroespes performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EEP has high quality earnings.

Growing Profit Margin: EEP's current net profit margins (-8.6%) are lower than last year (3.1%).


Past Earnings Growth Analysis

Earnings Trend: EEP is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.

Accelerating Growth: Unable to compare EEP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EEP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.3%).


Return on Equity

High ROE: EEP has a negative Return on Equity (-3.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Euroespes's financial position?


Financial Position Analysis

Short Term Liabilities: EEP's short term assets (€4.2M) exceeds its short term liabilities (€1.7M)

Long Term Liabilities: EEP's short term assets (4.2M) exceeds its long term liabilities (2.3M)


Debt to Equity History and Analysis

Debt Level: EEP's debt to equity ratio (35.8%) is considered satisfactory

Reducing Debt: EEP's debt to equity ratio has increased from 17.3% to 35.8% over the past 5 years.

Debt Coverage: EEP's debt is not well covered by operating cash flow (1.4%).

Interest Coverage: Insufficient data to determine if EEP's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: EEP has a high level of physical assets or inventory.

Debt Coverage by Assets: EEP's debt is covered by short term assets (assets are 1.3x debt).


Next Steps

Dividend

What is Euroespes's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%5.6%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EEP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EEP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EEP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EEP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EEP's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

What is the CEO of Euroespes's salary, the management and board of directors tenure and is there insider trading?


CEO

Euroespes has no CEO, or we have no data on them.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Ramón Cacabelos García

    Chairman of the Board of Directors

    • Tenure: 0yrs
  • José Antonio Rodríguez Romero

    Executive Director

    • Tenure: 0yrs

Board Members

  • Ramón Cacabelos García

    Chairman of the Board of Directors

    • Tenure: 0yrs
  • Valentín Diez Llorente

    Director

    • Tenure: 0yrs
  • Ángel Riesgo Alcalde

    Director

    • Tenure: 0yrs
  • Pablo Álvarez de Linera Granda

    Independent Director

    • Tenure: 0yrs
  • Juan Fernández de Sanmamed Sampedro

    Director

    • Tenure: 0yrs
  • José Pablo Cacabelos Pérez

    Director

    • Tenure: 0yrs
  • Juan Carlos Escurís Villa

    Director

    • Tenure: 0yrs
  • Aquilino Pérez Puga

    Independent Director

    • Tenure: 0yrs
  • José Antonio Rodríguez Romero

    Executive Director

    • Tenure: 0yrs

Company Information

Euroespes, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Euroespes, S.A.
  • Ticker: EEP
  • Exchange: BME
  • Founded: 1991
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €6.491m
  • Shares outstanding: 10.47m
  • Website: https://www.euroespes.com

Number of Employees


Location

  • Euroespes, S.A.
  • Santa Marta de Babío s/n
  • Bergondo
  • A Coruña
  • Galicia
  • 15165
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EEPBME (Bolsas y Mercados Espanoles)YesShare CapitalESEURFeb 2011

Biography

Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The company of ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/11 21:16
End of Day Share Price2019/11/11 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.